GlaxoSmithKline issued assurances today that its swine flu shot will be approved by federal regulators "as soon as possible."
On Tuesday the Food and Drug Administration approved vaccines made by four of the five companies expected to manufacture swine flu vaccines. London-based GSK, which has its U.S. headquarters in Research Triangle Park, is the fifth company whose vaccine wasn't approved.
"It's a timing thing," Claire Brough, a GSK spokeswoman, told Bloomberg News today.
Health and Human Services Secretary Kathleen Sibelius said Tuesday that the fifth manufactuer's vaccine was expected to be approved soon. She didn't identify GSK by name.
Glaxo reported last month that it has a total of $250 million in orders for the vaccine from the federal government.
The manufacturers whose vaccine was approved are: CSL Ltd. of Australia, Switzerland's Novartis Vaccines, Sanofi Pasteur of France and Maryland-based MedImmune.